NCT06012695 - NBM-BMX Administered Orally to Patients with Solid Tumors or Newly Diagnosed Glioblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 11, 2023

Primary Completion Date

May 30, 2028

Study Completion Date

September 30, 2029

Conditions

Malignant NeoplasmMalignant Neoplasm of Brain

Interventions

DRUG

NBM-BMX Capsule

Each capsule contains 100 mg of the active ingredient.

DRUG

Temozolomide

TMZ will be administered orally at a 75 mg/m2 dose daily during concomitant therapy. In the maintenance period, days 1-5 of each cycle will be administered 150-200 mg/m2.

RADIATION

Standard radiotherapy

A total dose of 60 Gy will be administered in 6 weeks.

Trial Locations (5)

112

RECRUITING

Koo Foundation Sun Yat-Sen Cancer Center, Taipei

333

RECRUITING

Linkou Chang-Gung Memorial Hospital, Taoyuan

407

RECRUITING

Taichung Veterans General Hospital, Taichung

807

NOT_YET_RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

970

NOT_YET_RECRUITING

Hualien Tzu Chi Hospital, Hualien City